MDR1 Protein Explained: How This Cellular Pump Works

If you’re searching for mdr1 protein, the direct answer is this: MDR1 (also called P-glycoprotein or ABCB1) is an ATP-powered “efflux pump” that pushes drugs and foreign substances out of cells, limiting how far they spread in the body [1]. According to the National Center for Biotechnology Information (NCBI), the protein is encoded by the ABCB1 gene on chromosome region 7q21 and forms a 170 kDa structure with 12 transmembrane domains [6][8]. That single mechanism shapes how 100s of drugs behave inside human and animal bodies.

What the MDR1 protein actually is

The MDR1 protein, formally named P-glycoprotein (P-gp) and catalogued as multidrug resistance protein 1, is an ATP-dependent transporter that moves a wide range of foreign substances out of cells [1]. According to UniProt’s entry for the human protein (accession P13568), it is built from a 170 kDa monomer featuring 12 transmembrane domains and two ATP-binding sites that power the pumping action [2][6]. The structure matters: those two ATP-binding cassettes give the protein its formal family name, ABCB1, where “ABC” stands for ATP-Binding Cassette. As described by NCBI’s gene database, the ABCB1 gene sits on chromosomal region 7q21 [8]. Researchers describe P-gp as having likely evolved as a defense mechanism, expelling potentially harmful compounds before they accumulate inside sensitive tissue [1]. In practical terms, the protein behaves like a molecular bouncer at the cell membrane: it recognizes a remarkably broad set of substrates and ejects them using chemical energy. This broad substrate range is exactly why a single protein can influence the disposition of so many unrelated medications, a point the FDA addresses in its published drug-drug interaction guidance for industry.

How the MDR1 protein works in the body

P-glycoprotein is concentrated in specific tissues that function as gatekeepers. According to the published literature, it appears in the intestinal epithelium, the liver, the proximal tubule cells of the kidney, and the capillary endothelial cells forming the blood-brain and blood-testis barriers [1][9]. In each location it pushes substrates in a protective direction: back into the intestinal lumen, into bile ducts, into urinary filtrate, or back into capillaries [1][9]. The net effect is that the protein restricts how far its substrate drugs can penetrate into organs such as the brain, testes, and placenta [4]. This is not a minor detail for pharmacology. The U.S. Food and Drug Administration (FDA) lists P-gp among the key transporters that companies should evaluate during drug development because it influences absorption, distribution, and clearance. Solvo Biotechnology, a firm specializing in transporter assays, describes MDR1/P-gp as one of the most studied efflux transporters precisely because it sits at these barrier tissues [4]. When two drugs compete for the same pump, blood levels of one can rise unexpectedly. INDIGO Biosciences notes that MDR1 is central to clinically meaningful drug-drug interactions for this reason [9], which is why interaction screening is now standard practice.

Why MDR1 matters in cancer treatment

The protein earned its “multidrug resistance” name in oncology. According to the published review literature, cancer cells that express high levels of P-gp can become multidrug resistant by actively pumping chemotherapeutic drugs back out before they can work [1][7]. This is one documented mechanism behind treatment failure in certain tumors. The American Cancer Society reports that cancer remains the second-leading cause of death in the United States, with an estimated 2 million new cases projected nationally in the most recent year of data, underscoring why resistance mechanisms draw intense research interest. The picture is not uniform across tumor types, however. A study of prostate cancer cell lines found MDR1 detectable only in 22Rv1 cells, and the authors concluded that MDR1 is of less importance for drug resistance in prostate cancer than in other solid cancers [3]. That nuance matters for patients and clinicians: a resistance mechanism that dominates in one cancer may be marginal in another. A 2015 review also found that the effect of ABCB1 gene variants (polymorphisms) on P-gp expression and activity across tissues appears to be small [1]. In short, the protein is a real contributor to chemoresistance in some settings, but it is one factor among several rather than a universal explanation.

The MDR1 gene mutation in dogs

One of the most practical real-world applications of MDR1 knowledge involves pets, not people. According to the Cornell University College of Veterinary Medicine, a genetic variant in the canine ABCB1 gene changes P-glycoprotein and produces what is commonly called MDR1 drug sensitivity [5]. Dogs carrying this variant have a weakened blood-brain barrier pump, so certain drugs that should stay out of the brain instead accumulate, causing severe neurological reactions. The Collie Health Foundation documents that the variant is especially common in herding breeds such as Collies, Australian Shepherds, and Shetland Sheepdogs [10]. Affected drugs include some antiparasitics and chemotherapy agents at standard doses. The cost of genetic testing to confirm MDR1 status runs roughly $50–$120 through veterinary laboratories in the United States, a modest investment compared with the $1,000–$5,000+ price of emergency neurological care for a severe reaction. Cornell advises owners of at-risk breeds to test before administering high-risk medications and to share results with their veterinarian [5]. This is a clear example of pharmacogenetics in routine practice: a single gene test can change which drugs and doses are safe for an individual animal.

How to recognize MDR1-related drug interaction risks

Because P-glycoprotein handles such a broad set of substrates, MDR1-related interactions are a recurring concern in medicine. The FDA’s drug-drug interaction guidance directs manufacturers to test whether new compounds are substrates or inhibitors of P-gp, which is why product labeling often flags transporter effects. Here are red flags that warrant a closer look with a pharmacist or physician:

• Starting a new medication while already taking a drug labeled as a P-gp inhibitor or substrate.
• Unexplained increases in side effects after adding a second drug, suggesting blood levels rose.
• Use of narrow-therapeutic-index drugs (such as certain cardiac medications) alongside known transporter inhibitors.
• Combining prescription drugs with supplements; some botanical products alter P-gp activity.

According to the Centers for Disease Control and Prevention (CDC), nearly 70% of U.S. adults take at least one prescription medication, and about 1 in 4 take three or more, which multiplies interaction opportunities. A free tool worth using is the FDA’s drug labeling database, DailyMed, where transporter information appears in the clinical pharmacology section. Pharmacists at retail chains can also run interaction checks at no charge, a service worth using before any new prescription is filled.

What experts recommend

Pharmacology and clinical experts converge on a few practical principles regarding the MDR1 protein. First, treat transporter interactions as a routine safety check rather than an afterthought; the FDA’s published guidance establishes P-gp evaluation as a standard expectation during drug development, signaling its clinical weight. Second, experts caution against overstating the role of ABCB1 genetic variation in humans. As the 2015 review concluded, the effect of common ABCB1 polymorphisms on P-gp expression and activity appears to be small [1], so routine MDR1 genotyping in people is not currently a standard recommendation the way it is in at-risk dog breeds. Third, in oncology, specialists emphasize matching the resistance mechanism to the tumor type; the prostate cancer findings show MDR1 is a minor player there compared with other solid tumors [3]. For everyday consumers, the consensus advice is concrete: maintain a single up-to-date medication list, use one pharmacy when possible so the system flags interactions, and consult a licensed pharmacist before combining prescriptions, over-the-counter drugs, and supplements. According to Consumer Reports, medication reviews catch interactions that patients and even prescribers can miss across multiple providers. For pet owners of herding breeds, veterinary experts uniformly recommend MDR1 testing before high-risk drugs.

When to consult a professional about MDR1

Knowing when to escalate to a professional is the most actionable takeaway. For human medication concerns, contact a pharmacist or physician before starting any drug if you already take a medication with a narrow therapeutic index or a label noting P-gp effects. According to the CDC, adverse drug events lead to roughly 1.3 million emergency department visits annually in the United States, and a meaningful share involves preventable interactions. Cost is rarely a barrier to prevention: a pharmacist interaction review is typically free, while an emergency department visit for an adverse reaction runs $1,200–$2,600 versus $150–$200 at urgent care. For pet owners, the trigger is breed plus medication: if you own a Collie, Australian Shepherd, or other herding breed and your dog needs an antiparasitic or chemotherapy drug, ask your veterinarian about MDR1 testing first, as Cornell advises [5]. As of 2026, you can also file a complaint or report an adverse drug event through the FDA’s MedWatch program, and consumer issues with testing labs can be reported to the Better Business Bureau or the FTC consumer complaint database. The guiding rule: when a drug crosses paths with a known P-gp interaction or an at-risk genotype, get a professional review before the first dose rather than after a reaction.

Key facts and current research outlook

Several durable facts about the MDR1 protein are worth keeping straight. It is one protein with three common names: P-glycoprotein, multidrug resistance protein 1, and ABCB1 [1][2]. It is an ATP-dependent efflux pump of 170 kDa with 12 transmembrane domains and two ATP-binding sites [6]. It is encoded by the ABCB1 gene on chromosome 7q21 [8]. And it likely evolved as a cellular defense system against toxins [1]. Research continues on several fronts. According to the published literature indexed by NCBI’s PubMed, investigators are studying P-gp inhibitors as a strategy to reverse chemotherapy resistance, though no approach has become standard front-line therapy. Solvo Biotechnology and similar contract labs continue refining MDR1 transporter assays used in drug screening [4]. In immunology, researchers are examining whether MDR1 plays a friend-or-foe role in immune cell function [6]. The U.S. research pipeline is substantial: the National Institutes of Health (NIH) funds thousands of grants touching drug transport and resistance, reflecting an annual NIH budget exceeding $47 billion. For consumers, the bottom line as of 2026 is that MDR1 is a well-characterized, clinically relevant protein whose biggest everyday impact shows up in drug interactions and in canine drug sensitivity testing.

Frequently Asked Questions

What is the MDR1 protein in simple terms?

The MDR1 protein, also called P-glycoprotein or ABCB1, is a cellular pump that uses energy (ATP) to push drugs and foreign substances out of cells [1]. Think of it as a molecular bouncer stationed in your intestine, liver, kidney, and the barriers protecting your brain and testes. It limits how far certain drugs spread into sensitive organs [4]. According to UniProt, the human protein is a 170 kDa structure with 12 transmembrane domains [2][6]. Its job is largely protective, expelling potential toxins, but it also explains why some chemotherapy drugs get pumped out of cancer cells and stop working [1][7].

Is MDR1 the same as P-glycoprotein and ABCB1?

Yes. MDR1, P-glycoprotein (P-gp), and ABCB1 are three names for the same thing [1][2]. “MDR1” stands for multidrug resistance protein 1, the name used because the protein can make cancer cells resistant to multiple drugs [1]. “P-glycoprotein” describes its molecular nature, and “ABCB1” is the official gene name, reflecting its membership in the ATP-Binding Cassette transporter family [8]. According to NCBI, the ABCB1 gene sits on chromosome region 7q21 [8]. You will see different names used depending on whether a source is discussing the gene, the protein structure, or its drug-resistance role, but they all refer to one molecule.

How does MDR1 cause chemotherapy resistance?

Some cancer cells produce high levels of the MDR1 protein. According to the review literature, this pump actively ejects chemotherapy drugs from cancer cells before they can do their job, making the tumor multidrug resistant [1][7]. Because P-glycoprotein recognizes a broad range of substrates, a single overexpressing tumor can resist several unrelated drugs at once. The effect is not universal across cancers, though. A study found MDR1 was detectable in only one prostate cancer cell line (22Rv1) and concluded it matters less for prostate cancer than for other solid tumors [3]. Researchers continue studying P-gp inhibitors as a way to reverse this resistance.

Should my dog be tested for the MDR1 mutation?

If your dog is a herding breed, testing is strongly advised. According to Cornell University College of Veterinary Medicine, a variant in the canine ABCB1 gene changes P-glycoprotein and causes MDR1 drug sensitivity, leading to severe reactions to certain drugs [5]. The Collie Health Foundation reports the variant is common in Collies, Australian Shepherds, and Shetland Sheepdogs [10]. Affected dogs can react badly to some antiparasitics and chemotherapy drugs at normal doses. A genetic test costs roughly $50–$120, far less than the $1,000–$5,000+ for emergency neurological care. Test before giving high-risk medications and share results with your veterinarian.

Do MDR1 gene variations affect drug response in humans?

The evidence suggests the effect is modest. A 2015 review found that common ABCB1 polymorphisms have only a small effect on P-glycoprotein expression and activity across human tissues [1]. That is why routine MDR1 genotyping is not currently a standard recommendation in human medicine, unlike in at-risk dog breeds [5]. The more clinically relevant human concern is drug-drug interactions, where one medication blocks the P-gp pump and raises blood levels of another. The FDA directs drug makers to evaluate P-gp effects for this reason. If you take multiple medications, ask a pharmacist to screen for transporter interactions.

Which drugs interact with the MDR1 protein?

A broad set of medications are P-glycoprotein substrates or inhibitors, including certain cardiac drugs, antibiotics, antivirals, and chemotherapy agents [9]. Because the list is long and updated regularly, the practical step is to check rather than memorize. The FDA’s DailyMed labeling database lists transporter information in each drug’s clinical pharmacology section. According to the CDC, nearly 70% of U.S. adults take at least one prescription medication, so interaction risk is widespread. INDIGO Biosciences notes MDR1 is central to clinically meaningful drug-drug interactions [9]. Before combining any new prescription, over-the-counter drug, or supplement, ask a pharmacist to run a free interaction check.

Where in the body is the MDR1 protein found?

P-glycoprotein is concentrated in gatekeeper tissues. According to the published literature, it appears in the intestinal epithelium, liver, the proximal tubule cells of the kidney, and the capillary cells forming the blood-brain and blood-testis barriers [1][9]. In each spot it pumps substances in a protective direction: back into the gut, into bile, into urine, or back into the bloodstream [1][9]. This placement explains why MDR1 restricts drug entry into the brain, testes, and placenta [4]. Solvo Biotechnology describes it as one of the most studied efflux transporters precisely because of these barrier locations [4], which makes it a priority in drug development.